The 33-year-old Chinese entrepreneur successfully led the start-up CG Oncology to achieve an initial public offering, resulting in a market valuation of nearly 3 billion US dollars specifically for bladder cancer treatment.

由韩国SK集团(SK HOLDINGS) 支持的针对ESG的特殊目的并购公司SK Growth Opportunities正式向SEC提交了高达2亿美元的首次公开募股申请，股票代码SKGRU，拟在纳斯达克上市。